Kinase Chemistry – Just a year and a half behind the times.

R & D @ B I

Posted by kinasepro on September 13, 2008

With BIRB-796 a distant memory, BIBW-2992 in ph3 and given the new name Tovok, BIBF-1120 headed into ph3 and given the name Vargatef,  BI-2536 in multiple Ph2s, a new Ph1 Aurora inhibitor, and another backup PLK1 inhibitor undisclosed, but likely in-clinic or clinic-bound – what could possibly be next?

I can haz pyrimidines

PDK mod prolly from Berlex

2 Responses to “R & D @ B I”

  1. milkshake said

    It is rather easy to find a potent pyrimidine kinase compound (and the chemistry is simple) – but I am not sure about selectivity. This may or may not be a problem depending on therapeutic area (dirty-profile compounds are good for cancer, etc). Since the patent literature is choke-full of pyrimidines, you better have strong patent lawyers to help you navigate the overlapping claims…

    Also, I am delighted that Kinasepro is back and that the comments are enabled. As they say to the returning well-liked inmates “doin’ time here wasn’t the same without you”

  2. kinasepro said

    I miss the comments like yours, so I turned them on with an approval basis.

    non-constructive comments wont get approved to avoid any potential issues with our overly litigious society! I’d still rather see more cross talk from new blogs though…

Leave a Reply to kinasepro Cancel reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: